GMP-Focused Platform Processes For Microbial, pDNA, And mRNA

Mario Kraft, Director of Process Development at AGC Biologics' Heidelberg facility, shares insights into how we develop and implement platform processes to streamline the production of microbial, plasmid DNA, and messenger RNA products.

By leveraging standardized yet flexible approaches, we enhance efficiency, scalability, and regulatory compliance, ensuring a smooth transition from early development to large-scale manufacturing. In this discussion, Mario explores the key strategies, challenges, and innovations that drive process optimization, ultimately accelerating the path to market for these critical biotherapeutic products.